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The original article \[[@CR1]\] contains an error in the y-axes of Fig. [8](#Fig1){ref-type="fig"}'s sub-figures whereby 'CSF' is mistakenly mentioned instead of 'serum'.

The correct version of Fig. [8](#Fig1){ref-type="fig"} can be viewed ahead and should be considered in place of the original Fig. [8](#Fig1){ref-type="fig"}.

Fig. 8Significant reduction in GM1a and GD1a levels in serum from PD patients and significant reduction in all measured glycosphingolipids, except GlcCer, in serum from RBD patients. Levels of GlcCer (**a**), LacCer (**b**), Gb3 (**c**), Gb4 (**d**), GM3 (**e**), GM2 (**f**), GM1a (**g**) and GD1a (**h**) were determined in serum samples from control subjects (*n* = 15), PD patients (*n* = 30) and age-matched RBD patients (*n* = 30) with NP-HPLC (\* = *p* \< 0.05, \*\* = *p* \< 0.01, \*\*\* = *p* \< 0.001, \*\*\*\* = *p* \< 0.0001, one-way ANOVA). Data are presented as mean ± SD
